Access agreements signed between pharmaceutical and biotech companies around the world

DUBLIN, January 4, 2022 /PRNewswire/ — The “Global Autoimmunity Partnership 2014-2021: Agreement Trends, Players and Financials” report has been added to from offer.

Global Autoimmune Partnering 2014 to 2021 provides the comprehensive collection of autoimmune disease agreements signed between the world’s pharmaceutical and biotechnology companies since 2014.

Most of the agreements included in the report occur when a licensee obtains a right or option to license the product or technology from a licensor. More often than not these days, these agreements tend to be multi-component, including both collaborative R&D and an element of commercializing the results.

The report presents readers with comprehensive Autoimmune Disease Agreement trends, key players, and major agreement values ​​to understand how, why, and under what conditions companies are currently entering into Autoimmune Disease Agreements.

The report presents financial agreement term values ​​for Autoimmune agreements, if any, listed by global global values, upfront payments, milestones and royalties allowing readers to analyze and compare the value of current agreements.

The early chapters of this report provide direction of autoimmune transaction trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of autoimmune transaction trends since 2014, covering trends by year, type of transaction, stage of development, type of technology and therapeutic indication.

Chapter 3 includes an analysis of the terms of the financial agreement covering aggregate value, upfront payment, milestone payments and royalty rates.

Chapter 4 reviews the top autoimmune deals since 2014. Deals are listed by aggregate value. The chapter includes the top 25 most active autoimmune traders, along with a full list of the agreements to which they are party. When the agreement has an agreement contract published to the SEC, a link provides online access to the contract.

Chapter 5 provides full access to Autoimmune agreements since 2014 when an agreement contract is available, providing the user with direct access to contracts filed with SEC regulators. Each transaction title is linked via Weblink to an online version of the transaction record contract document, providing easy access to each contract document upon request.

Chapter 6 provides a comprehensive directory of all autoimmune partnership offerings by specific autoimmune target announced since 2014. The chapter is organized by specific autoimmune therapeutic target. Each transaction title is linked via Weblink to an online version of the transaction record and, where applicable, the contract document, providing easy access to each contract document upon request.

The report includes coverage of the following autoimmune diseases:

Multiple sclerosis, restless legs syndrome, dermatitis, eczema, alopecia, psoriasis, celiac disease, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, glomerulonephritis, endometriosis, immune thrombocytopenic purpura, neutropenia, graft versus host disease, scleroderma, systemic lupus erythematosus, Addison’s disease, type 1 diabetes, ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, uveitis, narcolepsy, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, sarcoidosis, Meniere’s disease and other disorders autoimmune.

Global Autoimmune Partnering 2014 to 2021 offers the reader the following key benefits:

  • In-depth understanding of autoimmune transaction trends since 2014
  • Access Autoimmune agreement title, initial data, milestones and royalties
  • Search hundreds of actual contracts between Autoimmune partner companies
  • Full access to over 950 links to actual autoimmune deals made by the world’s biopharmaceutical companies
  • In-Depth Review of Autoimmune Deals Made by the Top 25 Most Active Negotiators
  • Compare key terms of agreement that companies have agreed to in previous agreements
  • Identify key terms under which companies associate with autoimmune opportunities
  • Find out which companies are actively partnering with autoimmune opportunities

Main topics covered:


Chapter 1 Introduction

Chapter 2 – Autoimmune Transaction Trends
2.1. introduction
2.2. Autoimmune partnership over the years
2.3. Autoimmune partnership by transaction type
2.4. Autoimmune Partnership by Industry Sector
2.5. Autoimmune partnership by developmental stage
2.6. Autoimmune partnership by type of technology
2.7. Autoimmune partnership by therapeutic indication

Chapter 3 – Conditions of the financial agreement for the Autoimmune partnership
3.1. introduction
3.2. Financial Terms Disclosed for Autoimmune Partnership
3.3. Key values ​​of the autoimmune partnership
3.4. Autoimmune Deal Upfront Payments
3.5. Autoimmune Transaction Milestone Payments
3.6. Autoimmune Royalty Rates

Chapter 4 – Major Agreements and Autoimmune Negotiators
4.1. introduction
4.2. Most active in autoimmune partnerships
4.3. List of the most active traders in Autoimmune
4.4. Best Autoimmune Deals by Value

Chapter 5 – Directory of Autoimmune Contract Documents
5.1. introduction
5.2. Autoimmune partnership agreements when contract document is available

Chapter 6 – Autoimmune Dealmaking by Therapeutic Target
6.1. introduction
6.2. Offers by autoimmune therapeutic target

Annex 1 – Directory of Autoimmune offers by company AZ 2014 to 2021
Annex 2 – Directory of Autoimmune transactions by type of transaction 2014 to 2021
Appendix 3 – Directory of Autoimmune offers by stage of development 2014 to 2021
Annex 4 – Directory of Autoimmune offers by type of technology 2014 to 2021

For more information on this report, visit

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets

Related links

Source link

Comments are closed.